You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePractolol
Accession NumberDB01297
TypeSmall Molecule
GroupsApproved
DescriptionA beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias. [PubChem]
Structure
Thumb
Synonyms
(+-)-Practolol
1-(4-Acetamidophenoxy)-3-isopropylamino-2-propanol
4'-(2-Hydroxy-3-(isopropylamino)propoxy)acetanilide
N-(4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)acetamide
Practololum
Tocris-0831
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIISUG9176GRW
CAS number6673-35-4
WeightAverage: 266.3361
Monoisotopic: 266.16304258
Chemical FormulaC14H22N2O3
InChI KeyDURULFYMVIFBIR-UHFFFAOYSA-N
InChI
InChI=1S/C14H22N2O3/c1-10(2)15-8-13(18)9-19-14-6-4-12(5-7-14)16-11(3)17/h4-7,10,13,15,18H,8-9H2,1-3H3,(H,16,17)
IUPAC Name
N-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide
SMILES
CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1
Pharmacology
IndicationUsed in the emergency treatment of cardiac arrhythmias.
Structured Indications Not Available
PharmacodynamicsPractolol is a beta-adrenergic receptor antagonist that has been used in the emergency treatment of cardiac arrhythmias. Beta blockers inhibit normal epinephrine-mediated sympathetic actions, but have minimal effect on resting subjects. That is, they reduce the effect of excitement/physical exertion on heart rate and force of contraction and dilation of blood vessels.
Mechanism of actionLike other beta-adrenergic antagonists, practolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, practolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
antagonist
HumanP08588 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing.
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Practolol Action PathwayDrug actionSMP00669
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Practolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Practolol.Experimental, Illicit
AceclofenacAceclofenac may decrease the antihypertensive activities of Practolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Practolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Practolol.Approved
AcetohexamidePractolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Practolol.Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when Practolol is combined with Acetylcholine.Approved
AcetyldigitoxinPractolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Practolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Practolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Practolol.Experimental, Investigational
AlfentanilAlfentanil may increase the bradycardic activities of Practolol.Approved, Illicit
AlfuzosinPractolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Practolol.Approved, Vet Approved
AmbenoniumAmbenonium may increase the bradycardic activities of Practolol.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Practolol.Approved, Investigational
AmobarbitalThe serum concentration of Practolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Practolol can be decreased when combined with Amodiaquine.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Practolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Practolol.Approved
AnvirzelPractolol may increase the bradycardic activities of Anvirzel.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Practolol.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Practolol is combined with Arecoline.Experimental
AzapropazoneAzapropazone may decrease the antihypertensive activities of Practolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Practolol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Practolol.Approved, Investigational
BarbexacloneThe serum concentration of Practolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Practolol can be decreased when it is combined with Barbital.Illicit
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Practolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Illicit
BethanecholThe risk or severity of adverse effects can be increased when Practolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Practolol.Investigational
BL-1020BL-1020 may increase the hypotensive activities of Practolol.Investigational
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Practolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Practolol.Investigational
BucindololPractolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Practolol.Approved, Investigational
CabergolinePractolol may increase the vasoconstricting activities of Cabergoline.Approved
CarbacholThe risk or severity of adverse effects can be increased when Practolol is combined with Carbachol.Approved
CarprofenCarprofen may decrease the antihypertensive activities of Practolol.Approved, Vet Approved, Withdrawn
CarvedilolPractolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Practolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Practolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Practolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Practolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the hypotensive activities of Practolol.Approved, Vet Approved
ChlorpropamidePractolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Practolol.Approved
CoumaphosCoumaphos may increase the bradycardic activities of Practolol.Vet Approved
CurcuminCurcumin may decrease the antihypertensive activities of Practolol.Investigational
D-LimoneneD-Limonene may decrease the antihypertensive activities of Practolol.Investigational
DapoxetineThe serum concentration of Practolol can be increased when it is combined with Dapoxetine.Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Practolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Practolol.Approved
DeslanosidePractolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Practolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Vet Approved
DichlorvosDichlorvos may increase the bradycardic activities of Practolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Practolol.Approved, Vet Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Practolol.Approved
DigitoxinPractolol may increase the bradycardic activities of Digitoxin.Approved
DigoxinPractolol may increase the bradycardic activities of Digoxin.Approved
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
DiltiazemDiltiazem may increase the hypotensive activities of Practolol.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Practolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Practolol.Approved
DonepezilDonepezil may increase the bradycardic activities of Practolol.Approved
DoxazosinPractolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Practolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Practolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Investigational
DuloxetineThe serum concentration of Practolol can be increased when it is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Practolol.Investigational
E6201E6201 may decrease the antihypertensive activities of Practolol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Practolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Practolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Practolol.Approved
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Nutraceutical, Withdrawn
EPIBATIDINEThe risk or severity of adverse effects can be increased when Practolol is combined with EPIBATIDINE.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Practolol.Approved
Ergoloid mesylatePractolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovinePractolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Practolol.Approved, Investigational
EtodolacEtodolac may decrease the antihypertensive activities of Practolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Practolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
EtoperidoneThe serum concentration of Practolol can be increased when it is combined with Etoperidone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Practolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Practolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Practolol.Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Practolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Practolol.Approved
FentanylFentanyl may increase the bradycardic activities of Practolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Practolol.Vet Approved
FingolimodPractolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Practolol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Practolol.Vet Approved
FluoxetineThe serum concentration of Practolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Practolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Practolol.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Practolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Practolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Practolol.Approved, Nutraceutical
GlibornuridePractolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazidePractolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepiridePractolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizidePractolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidonePractolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepidePractolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburidePractolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Practolol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Investigational
HexobarbitalThe serum concentration of Practolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Practolol.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Practolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Practolol.Investigational
HydroxychloroquineThe metabolism of Practolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Practolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Practolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Practolol.Approved
IndalpineThe serum concentration of Practolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndomethacinIndomethacin may decrease the antihypertensive activities of Practolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Practolol.Withdrawn
IndoraminPractolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkPractolol may increase the hypoglycemic activities of Insulin Pork.Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Practolol.Approved, Withdrawn
IsoxicamIsoxicam may decrease the antihypertensive activities of Practolol.Withdrawn
KebuzoneKebuzone may decrease the antihypertensive activities of Practolol.Experimental
KetoprofenKetoprofen may decrease the antihypertensive activities of Practolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Practolol.Approved
LabetalolPractolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LeflunomideLeflunomide may decrease the antihypertensive activities of Practolol.Approved, Investigational
LevomilnacipranThe serum concentration of Practolol can be increased when it is combined with Levomilnacipran.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Practolol.Approved, Vet Approved
LisofyllineLisofylline may decrease the antihypertensive activities of Practolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Practolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Investigational
LornoxicamLornoxicam may decrease the antihypertensive activities of Practolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Practolol.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Practolol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Practolol.Approved
MalathionMalathion may increase the bradycardic activities of Practolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Practolol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Practolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Practolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Practolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Practolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Practolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Practolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Practolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Practolol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Practolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Practolol is combined with Methacholine.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Practolol.Investigational
MethohexitalThe serum concentration of Practolol can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Practolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Practolol.Investigational
MethylphenobarbitalThe serum concentration of Practolol can be decreased when it is combined with Methylphenobarbital.Approved
MidodrinePractolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Practolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Practolol.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Practolol.Investigational
MoricizineMoricizine may increase the hypotensive activities of Practolol.Approved, Withdrawn
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Practolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Practolol.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Practolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Practolol.Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Practolol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Practolol.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the antihypertensive activities of Practolol.Investigational
NefazodoneThe serum concentration of Practolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Practolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Practolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Practolol is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Practolol is combined with Nicotine bitartrate.Approved
NifedipineNifedipine may increase the hypotensive activities of Practolol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Practolol.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Practolol.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Practolol.Investigational
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Practolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Practolol.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Practolol.Vet Approved
OuabainPractolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Practolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Practolol.Withdrawn
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Practolol.Approved
ParoxetineThe serum concentration of Practolol can be increased when it is combined with Paroxetine.Approved, Investigational
PentobarbitalThe serum concentration of Practolol can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerazinePerazine may increase the hypotensive activities of Practolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Vet Approved, Withdrawn
PerphenazinePerphenazine may increase the hypotensive activities of Practolol.Approved
PhenobarbitalThe serum concentration of Practolol can be decreased when it is combined with Phenobarbital.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Practolol.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Practolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Practolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Practolol.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Practolol.Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Practolol.Approved, Investigational
PrazosinPractolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Practolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Practolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Practolol.Approved, Vet Approved
PromazinePromazine may increase the hypotensive activities of Practolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Practolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Practolol.Approved
PropafenoneThe serum concentration of Practolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Practolol.Vet Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Practolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Practolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Practolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Practolol.Approved
ReserpineReserpine may increase the hypotensive activities of Practolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Practolol.Experimental, Investigational
RifampicinThe serum concentration of Practolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Practolol can be decreased when it is combined with Rifapentine.Approved
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Investigational
RivastigmineRivastigmine may increase the bradycardic activities of Practolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Practolol.Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Investigational
SalicylamideSalicylamide may decrease the antihypertensive activities of Practolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Practolol.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Practolol.Approved
SecobarbitalThe serum concentration of Practolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Practolol.Approved, Investigational
SertralineThe serum concentration of Practolol can be increased when it is combined with Sertraline.Approved
SilodosinPractolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SRT501SRT501 may decrease the antihypertensive activities of Practolol.Investigational
SufentanilSufentanil may increase the bradycardic activities of Practolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Practolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Practolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Practolol.Approved, Withdrawn
TacrineTacrine may increase the bradycardic activities of Practolol.Withdrawn
TamsulosinPractolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Practolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Practolol.Vet Approved
TerazosinPractolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Practolol.Approved
ThiamylalThe serum concentration of Practolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Practolol.Withdrawn
ThiopentalThe serum concentration of Practolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThioridazine may increase the hypotensive activities of Practolol.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Practolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Practolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
TolazamidePractolol may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamidePractolol may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Practolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Practolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Practolol.Approved, Investigational
TrichlorfonTrichlorfon may increase the bradycardic activities of Practolol.Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Practolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Practolol.Approved, Vet Approved
TrimazosinPractolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Practolol.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Practolol.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Practolol.Investigational, Withdrawn
VareniclineThe risk or severity of adverse effects can be increased when Practolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Practolol can be increased when it is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Practolol.Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Practolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Practolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Practolol can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Practolol.Withdrawn
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC07AB01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9472
Blood Brain Barrier-0.8609
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.589
P-glycoprotein inhibitor INon-inhibitor0.8705
P-glycoprotein inhibitor IINon-inhibitor0.9147
Renal organic cation transporterNon-inhibitor0.9484
CYP450 2C9 substrateNon-substrate0.781
CYP450 2D6 substrateNon-substrate0.5082
CYP450 3A4 substrateNon-substrate0.6487
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.6103
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9289
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9268
Ames testNon AMES toxic0.9153
CarcinogenicityNon-carcinogens0.8402
BiodegradationNot ready biodegradable0.9564
Rat acute toxicity1.9187 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9917
hERG inhibition (predictor II)Non-inhibitor0.898
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point134-136 °CPhysProp
logP0.79HANSCH,C ET AL. (1995)
Caco2 permeability-6.05ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.49 mg/mLALOGPS
logP0.53ALOGPS
logP0.83ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)14.03ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area70.59 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity75.24 m3·mol-1ChemAxon
Polarizability30.39 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as acetanilides. These are organic compounds containing an acetamide group conjugated to a phenyl group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassAnilides
Direct ParentAcetanilides
Alternative Parents
Substituents
  • N-arylamide
  • Acetanilide
  • Phenol ether
  • Alkyl aryl ether
  • Acetamide
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Carboxamide group
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Abrahamsson T: The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat. Br J Pharmacol. 1986 Apr;87(4):657-64. [PubMed:2871880 ]
  2. Keyrilainen O, Uusitalo A: A comparative study of three beta 1-adrenoreceptor blocking drugs with different degree of intrinsic stimulating activity (metoprolol, practolol and H 87/07) in patients with angina pectoris. Ann Clin Res. 1978 Aug;10(4):185-90. [PubMed:30388 ]
  3. Saarnivaara L, Lindgren L, Hynynen M: Effects of practolol and metoprolol on QT interval, heart rate and arterial pressure during induction of anaesthesia. Acta Anaesthesiol Scand. 1984 Dec;28(6):644-8. [PubMed:6524278 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Buxton IL, Brunton LL: Direct analysis of beta-adrenergic receptor subtypes on intact adult ventricular myocytes of the rat. Circ Res. 1985 Jan;56(1):126-32. [PubMed:2857116 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 08:19 / Updated on August 17, 2016 12:23